tbuckley/cabot-search huggingface dataset:
FRI0434 Prevalence of Structural Cardiac Disease and Diastolic Dysfunction in Axial Spondyloarthritis: A Prospective Case-Control Study
Authors: R. Reejhsinghani, K.M. Brown, N.B. Schiller, G. Yoon, E. Foster, L.S. Gensler
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Aortic dilation, aortic insufficiency (AI) and diastolic dysfunction (DD) have been described as complications of Ankylosing Spondylitis (AS), although their prevalence remains uncertain. Newer therapies for Axial Spondyloarthritis (AxSpA) may have further influenced the prevalence of cardiac disease. Prior studies were small and uncontrolled, resulting in controversial recommendations for routine echocardiographic screening of AxSpA patients. <h3>Objectives</h3> The objective of our study was to describe the prevalence of structural heart disease (SHD) and DD among a cohort of AxSpA patients matched with a healthy control population. <h3>Methods</h3> Prospective transthoracic echocardiograms were performed on 125 AxSpA patients and 56 age-matched controls. Leading edge aortic root (AoR) measurements were made and normalized for body size. Measurements were also taken at the aortic annulus, sino-tubular junction and ascending aorta. DD was graded according to the American Society of Echocardiography guidelines. Chi square tests and Wilcoxan rank sum analyses were used in the univariate analysis. A subgroup analysis was performed in a matched group of 90 AS patients meeting the modified New York criteria and 45 healthy controls. <h3>Results</h3> Participants were 68% male with a mean age of 43 ± 12 years. Mean AxSpA disease duration was 18 ± 12 years. mSASSS for the overall AxSpA population was 7.1 ± 14.5 units and was 9.9 ± 16.5 units for the AS population. Mean AoR diameter was 3.29 ± 0.36 cm for cases and 3.24 ± 0.32 cm for controls. There were no differences in linear aortic measurements, AI or DD between groups. The subgroup analysis of AS patients alone did not show differences in any of these outcomes when compared to controls. <h3>Conclusions</h3> AxSpA patients showed no differences in AoR size or AI when compared with healthy controls. While there were differences among individual measurements used to assess diastology, there is no clinically relevant difference in DD between groups. These findings are the first evidence-base to support the recommendations against routine echocardiographic screening in asymptomatic AxSpA patients. <h3>References</h3> Nagueh SF, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography 22.2(2009):107–133. <h3>Disclosure of Interest</h3> None declared
Long-Term Outcome After Matched Allogeneic Hematopoietic Stem Cell Transplantation for Fanconi Anemia On Behalf of the FA Committee of the Severe Aplastic Anemia Working Party (SAA WP) and the Pediatric Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Authors: Régis Peffault de Latour, Raphael Porcher, Jean-Hugues Dalle, Mahmoud Aljurf, Elisabeth T Korthof, Johanna Svahn, Roelof Willemze, C Barrenetxea, Valerie Mialou, Jean Soulier, Enrico Cappelli, Judith C. W. Marsh, Christina Peters, Gerard Socie, Carlo Dufour
Journal: Blood (2011)
EBV Infection and Altered Control of Apoptotic Pathways in Posttransplant Lymphoproliferative Disorders (PTLD).
Authors: Maria-Rosa Ghigna, Tajna Reineke, Patricia Rince, Monique Fabre, Emmanuel Jacquemin, Antoine Durrbach, Didier Samuel, Irène Joab, Caroline Besson, Catherine Guettier, Marianne Tinguely, Marco Lucioni, Marco Paulli, Martine Raphael
Journal: Blood (2009)
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.
Authors: Monica Bocchia, Marzia Defina, Micaela Ippoliti, Elisabetta Abruzzese, Fausto Castagnetti, Mario Tiribelli, Gianantonio Rosti, Massimo Breccia, Malgorzata Monika Trawinska, Rosaria Crupi, Lara Aprile, Marzia Salvucci, Claudia Baratè, Antonella Gozzini, Michela Rondoni, Alfonso Zaccaria, Giuliana Alimena, Valeria Santini, Giorgina Specchia, Renato Fanin, Alessandro Gozzetti, Francesco Lauria
Journal: Blood (2010)
AB1085-HPR Audit of Nurse-Led DGH Rheumatology Advice Line:
Authors: T. Bellerby, D. Stevens, T. Arnold, L. Kerton, G. Ortiz, E. Price, D. Collins, A. Ahmed, S. Carty, L. Williamson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> We introduced a nurse led Rheumatology Advice Line in 2004 to offer telephone advice to patients with inflammatory arthritis (1). Since then there has been a year-on-year increase in the number and complexity of calls, putting unsustainable demand on service and staff. A service review in April 2014 demonstrated one third of calls were inappropriate, including calls about the Home delivery service, appointment times and general practice related problems. We therefore changed the recorded message with the expectation that the helpline be used for telephone consultations concerning: medication side effects and effectiveness; flares of arthritis; possible complications of biologics and DMARDs; results of blood and X-Ray tests to avoid outpatient appointments. We audited the use of the Advice Line. <h3>Methods</h3> We documented the number of calls to the Advice Line from 2004–2014. The recorded message for the Advice Line was altered in May 2014. We audited the calls in April 2014 and compared with data from calls between May and December 2015. All calls were documented and categorised as: Patient calls leading to clinic appointment; Patient calls with advice give related to medication or inflammatory arthritis; GP or district nurse calls with advice given; Home delivery related; Inappropriate calls (including non rheumatological conditions, appointment time related, in-house calls). We also documented whether letters were generated and made a judgement about whether Consultant or GP consultation had been avoided <h3>Results</h3> The total annual number of calls increased from 438 in 2004; 2752 in 2006; 3074 in 2008; 2817 in 2010; 3857 in 2012; 3210 in 2014. After the recorded message was changed, the number of inappropriate calls fell from 97/311 (31.2%) in April 2014 to 8/258 (3.1%) from April to December 2015. However the number of appropriate calls rose from 131/311 (42.1%) in April 2014 to 194/258 (75.2%). The complexity and time needed to deal with calls has also increased. <h3>Conclusions</h3> The Rheumatology Nurse Practitioner led Advice Line provides a valuable clinical service as an adjunct to face to face consultation. This audit suggests a saving over 100 face-to-face consultations per month. Changing the Advice Line message led to a fall in the number of inappropriate calls but the number and complexity of calls continues to increase. This will need to be reflected in future service evaluation. <h3>References</h3> RA Hughes. Telephone Helplines in Rheumatology Rheumatology, Vol 42. 197–199 (2003) <h3>Disclosure of Interest</h3> None declared
Case 11-1974
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Bernard R. Aserkoff, James J. Galdabini
Journal: New England Journal of Medicine (1974)

Presentation of CaseA 31-year-old woman was admitted to the hospital because of fever.At the age of 10 years she entered another hospital because of hematemesis. The physical examination disclosed splenomegaly and massive hepatic enlargement, and an upper gastrointestinal series revealed esophageal varices. A splenectomy, a splenorenal shunt and a liver biopsy were performed; microscopical examination disclosed congestive splenomegaly and congenital cystic disease of the liver. Nine years later she was admitted to a second hospital because of fever and was found to have septicemia due to Escherichia coli, with multiple septic emboli to the lower lobe of . . .
OP0270 Targeting IL-23 Can Attenuate Progression of Spinal Ankylosis in Ankylosing Spondylitis
Authors: S. Jo, B.S. Koo, B.S. Koo, I.-H. Sung, I.-H. Sung, Y.-S. Park, Y.-S. Park, C.-B. Choi, C.-B. Choi, T.-H. Kim, T.-H. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> IL-23 has been implicated in the development of ankylosing spondylitis (AS). The role of IL- 23 in AS pathogenesis has emerged as a therapeutic target. This study aimed to clarify that anti IL-23 blockade can prevent progression of bony ankylosing in AS patients. <h3>Objectives</h3> We investigated endoplasmic reticulum (ER) stress and IL-23 cytokine could play a role in human bone-derived osteoblast cells and blocking it leads to regulation of bone-related genes and/or preventing bone ankylosis in AS. <h3>Methods</h3> Primary human osteoblast cells were isolated from diced bones of facet joints which were taken from surgical operation of 8 AS patients and 8 healthy controls (HC). The tissues of facet joints in AS were stained and compared with those of HC. Osteoblast differentiation- and ER stress-related genes were determined by quantitative RT-PCR, immunoblotting, immunofluorescence, and immunohistochemistry. Osteoblast activity of all bones-derived osteoblast cells was confirmed by Alkaline Phosphatase activity (ALP) and Alizarin Red (ARS) staining. The ER stress by BIX, selective BIP inducer X, in the regulation of IL-23 expression and secretion was evaluated by quantitative RT-PCR and ELISA. <h3>Results</h3> We found that elevated RUNX2, BIP, and IL-23 protein expressions were observed at osteoblast cells in human AS compared to HC. In addition, mRNA levels of bone differentiation (ALP, BMP2, COL1A, RUNX2, C/EBPβ, OPG, and OCN) and ER stress (BIP and CHOP)-related genes were highly expressed in human AS. In particular, IL-23 and RUNX2 expressions were significantly increased in AS. BIX-mediated ER stress stimulated induction of osteoblast activity and IL-23 secretion via modulating RUNX2 and C/EBPβ genes. Intriguingly, RUNX2 Knockdown by shRNA impeded ER stress-induced effects. Moreover, osteoblast activity and RUNX2 expression in AS were significantly reduced by IL-23 blockers, but not TNFα blockers. <h3>Conclusions</h3> This is the first report to show that ER stress, osteoblastic activity, and IL-23 expression in AS were increased compared to HC, suggesting that sustained ER stress induces osteoblast activity and IL-23 expression. Notably, these effects in AS were reduced by IL-23 blockade. Taken together, our results supported that blocking IL-23 may represent a promising therapeutic target to assist and prevent bony progression in AS. <h3>Disclosure of Interest</h3> None declared
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.
Authors: Asher Chanan-Khan, Jeffrey Wolf, Mecide Gharibo, Sundar Jagannath, Nikhil C. Munshi, Kenneth C. Anderson, Debbie Manfredi, Kelvin P. Lee, Kena C Miller, Robin Guild, Sybil Zildjian, Albert Qin, James O'Leary, Robert Vescio
Journal: Blood (2009)
Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer
Authors: J. Alejandro Rauh-Hain, Alexander Melamed, Alexi Wright, Allison Gockley, Joel T. Clemmer, John O. Schorge, Marcela G. del Carmen, Nancy L. Keating
Journal: JAMA Oncology (2016)

Uncertainty remains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy (NACT) for advanced-stage epithelial ovarian cancer (EOC).To compare overall survival of PCS vs NACT in a large national population of women with advanced-stage EOC.Retrospective cohort study of women with stage IIIC and IV EOC diagnosed between 2003 and 2011 treated at hospitals across the United States reporting to the National Cancer Data Base. We focused on patients 70 years or younger with a Charlson comorbidity index of 0 who were likely candidates for either treatment.Initial treatment approach of PCS vs NACT, examined using an intent-to-treat analysis.Overall survival, defined as months from cancer diagnosis to death or date of the last contact. We used propensity score matching to compare similar women who underwent PCS and NACT. The association of treatment approach with overall survival was assessed using the Kaplan-Meier method and the log-rank test. We assessed whether the findings were influenced by differences in the prevalence of an unobserved confounder, such as limited performance status (Eastern Cooperative Oncology Group 1-2), preoperative disease burden, and BRCA status.Among 22 962 patients (mean [SD] age, 56.12 [9.38] years), 19 836 (86.4%) received PCS and 3126 (13.6%) underwent NACT. We matched 2935 patients treated with NACT with similar patients who received PCS. The median follow-up was 56.5 (95% CI, 54.5-59.2) months in the PCS group and 56.3 (95% CI, 54.5-59.8) months in the NACT group in the propensity-matched cohort. Among propensity score-matched groups, the median overall survival was 37.3 (95% CI, 35.2-38.7) months in the PCS group and 32.1 (95% CI, 30.8-34.1) months in the NACT group (P < .001). However, if the NACT group had a higher proportion of women with performance statuses of 1 to 2 compared with those who underwent PCS (60% vs 50%), the association of PCS and improved survival would not be statistically significant.Primary cytoreductive surgery was associated with improved survival compared with NACT in otherwise healthy women with advanced-stage epithelial ovarian cancer aged 70 years or younger. The lower survival in women who received NACT could be explained by a higher prevalence of limited performance status in women undergoing NACT.
IMST-36. DEVELOPMENT OF MURINE IL13Rα2-TARGETED CAR T CELLS (mIL13BBζ) FOR ASSESSMENT OF CAR T CELL THERAPY IN SYNGENEIC GLIOMA MODELS
Authors: Darya Alizadeh, Xin Yang, Sarah Wright, Wen-Chung Chang, Stephen Forman, Christine Brown
Journal: Neuro-Oncology (2016)

Malignant gliomas are one of the most deadly brain tumors with limited therapeutic options. Current treatments have modestly improved the median survival of glioblastoma (GBM) patients; therefore, novel therapeutic options are urgently needed. Immunotherapy, specifically chimeric antigen receptor (CAR) T cell therapy, has emerged as a promising strategy to selectively eliminate cancer cells. Our team has developed a second-generation CAR T cell therapy directed against the GBM-associated antigen, IL13Rα2, which is currently in a phase I clinical trial. While the ongoing clinical trial has provided evidence for safety and potency of IL13Rα2-targeted CAR T cells, factors such as immunosuppressive tumor microenvironment may dampen the potency of adoptively transferred T cells and negatively impact the overall response rates. Therefore, we have developed a murine IL13Rα2-targeted CAR T cell platform to preclinically evaluate parameters that impact the efficacy of CAR T cell therapy. Analogous to the human IL13Rα2-CAR being evaluated in clinical trial, the murine IL13Rα2-CAR (mIL13BBζ) is comprised of a mouse IL-13(E12Y) tumor-targeting domain, and murine 4-1BB and CD3ζ signaling domains. The T2A skip sequence separates the CAR from a truncated CD19 (CD19t) for cell tracking. Isolated T cells were lentivirally transduced 24 hours after activation (anti-CD3/anti-CD28 beads; IL2). Flow cytometric analysis following transduction revealed expression of CD19 on 50-58% of the cells. To demonstrate cytotoxic function of mIL13Rα2-CAR T lymphocytes, a murine glioma (K-Luc) was transduced to stably express mIL13Rα2. In vitro killing assay showed mIL13Rα2 efficiently targeted K-Luc-IL13Rα2+cells, while mock T cells displayed undetectable response. Next mIL13Rα2-CAR T cell function in syngeneic immunocompetent mouse models will be evaluated. Overall, the development of mIL13BBζ CAR T cells and its applications will be a powerful tool to assess factors that may impact the efficacy of CAR T cells and provide invaluable information critical for combination therapies and clinical trial design.
Priming with Myeloid Growth Factors Enhances CD33 Expression, Decreases P-Glycoprotein Activity, and Improves Efficacy of Gemtuzumab Ozogamicin against Acute Myeloid Leukemia (AML) Colony Forming Cells (CFC)
Authors: Roland B. Walter, Sarah E. Fairchild, David A. Flowers, Tom C. Hong, Irwin D. Bernstein
Journal: Blood (2008)
Severe Chronic Neutropenia in Korean Children.
Authors: Mee Jeong Lee, Hyeon Jin Park, Hee Young Shin, Hyoung Jin Kang, Hong Hoe Koo, Hoon Kook, Young Joo Kwon, Sun Young Kim, Soon Ki Kim, Heung Sik Kim, Hyung Nam Moon, Kyung Duk Park, Byung-Kiu Park, Seong Shik Park, Eun Sil Park, Hee Jo Baek, Jong Jin Seo, Ki Woong Sung, Joon Sup Song, Hyo Seop Ahn, Sung Chul Won, Keon Hee Yoo, Chuhl Joo Lyu, Kun Soo Lee, Soo Hyun Lee, Young Ho Lee, Yeon Jung Lim, Young Tak Lim, Jae-Young Lim, Ho Joon Im, Dong kyun Han, Tai Ju Hwang
Journal: Blood (2009)
Local Experience with Autologous Stem Cell Transplant in Multiple Myeloma at a Public Institution (Instituto Nacional de Cancerologia)
Authors: Eduardo Cervera, Jorge Carlos Torres, Nidia P. Zapata, Juan Rafael Labardini, Jose Ramiro Espinoza, Magnolia Vieyra, Antonio Sosa, Valentin Lozano, Myrna Candelaria, Abelardo Meneses
Journal: Blood (2015)
Abstract 12891: Creating a Gateway Into Digital Health for Older Patients who are Technology Impaired
Authors: Richard V Milani, Carl J Lavie, Robert M Bober, Alexander R Milani
Journal: Circulation (2016)

Introduction: Older patients with chronic disease such as hypertension (HTN) may benefit from utilizing home based technology (tech) to monitor and improve disease control, but may forgo these opportunities due to concerns and/or fears over lack of tech skills. Reducing these concerns by providing a free service where use of newer technologies can be introduced and taught may provide opportunities for better HTN management and patient engagement. Purpose: To evaluate whether tech impaired patients with uncontrolled HTN could actively participate and achieve BP control similar to those without tech limitations as part of a digital HTN program. Methods: We created a free health tech “genius bar” called the “O Bar” where patients could be taught how to use a wireless BP unit that transmitted data automatically to the electronic medical record. Patients were assessed at entry as to their tech “savviness” based on capability to email, shop on-line, and use text. All patients were instructed how to take their BP using a smartphone app as well as use of a basic patient portal app. The O Bar was available to all patients for free instruction on the use of health apps and home based monitoring. Results: Of the 247 patients enrolled into the digital HTN program, 18% (44) were labeled as tech impaired. Patients were asked to submit 3-5 BP readings per week from home and intervention consisted of lifestyle and medication management by a clinical pharmacist and a health coach. Conclusions: 1. Tech impaired patients were older and had lower health literacy but were able to successfully submit weekly BP measurements and achieve BP control, similar to tech savvy patients. 2. Older patients with poor tech skills should not be dissuaded from enrolling into a digital tech management program provided health systems are willing to provide basic tech education.
PWE-122 Non-Bowel Cancer Screening Colonoscopy HasInferior Rates of Polyp Retrieval and Adenoma Detection than Bowel Cancer Screening
Authors: V Sehgal, TN Jones, LLY Ping, A Robbins, A Edwards-Bailey, LA Belón, M Rodriguez-Justo, K Besherdas
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy within the Bowel Cancer Screening Programme (BCSP) is scrutiny to high national standards and enhanced quality assurance. These include accredited colonoscopists who are required to have passed a summative assessment and perform more than 150 BCSP colonoscopies annually. Additionally, extended time allocation to allow for longer withdrawal times, are thought to further improve quality. In contrast, patients attending for non-BCSP (NBCSP) may have their colonoscopy performed by any endoscopist with less time allocation. Adenoma detection rate (ADR) a key quality indicator of colonoscopy with the strongest association to post-colonoscopy colorectal cancer. We hypothesised that patients within the BCSP had a superior ADR to NBCSP patients and consequently, a higher quality colonoscopy. <h3>Methods</h3> Patients attending for BCSP and NBCSP colonoscopy over a 2 year period (August 2013–July 2015) at University College London Hospital were identified. NBCSP patients aged 60–74 years were only included in our analyses. BCSP colonoscopy was performed by one of 6 BCSP accredited colonoscopists. NBCSP colonoscopy was performed either by a nurse endoscopist, registrar (including those in training) or a consultant. An in-house endoscopy and BCSP database were used to record polyp detection (PDR), polyp retrieval (PRR), adenoma to polyp detection rate (APDR) and adenoma detection rates (ADR) in both groups. The Student’s t-test was used and p &lt; 0.05 was statistically significant. <h3>Results</h3> A total of 1,547 and 5,898 patients attended for BCSP and NBCSP colonoscopy. In the NBCSP group, 1,692 (29%) were aged 60–74 years and were only included in our analyses. The polyp detection rate (PDR) in the BCSP group was significantly higher (931/1547, 60%) than in the NBCSP group (465/1692, 27%), p &lt; 0.05. In the BCSP group, a total of 2,094 polyps were removed. In the NBCSP group, 1,048 polyps were removed. The PRR was significantly higher in the BCSP patients (2086/2094, 99%) compared to NBCSP patients (764/1048, 76%), p &lt; 0.001. The APDR was similar between both groups - BCSP 1,542/2,086 (74%), NBCSP 572/764 (75%). In contrast, the ADR was significantly higher in the BCSP cohort (735/1547 patients had &gt;=1 adenoma, 48%) compared to the NBCSP group (337/1692 patients had &gt;=1 adenoma, 20%), p &lt; 0.05. <h3>Conclusion</h3> To our knowledge, this is one of the largest multi-operator studies comparing quality indicators in BCSP and NBCSP patients. Our study has demonstrated that NBCSP patients are more likely to have a significantly lower PRR and ADR than their BCSP counterparts. Further efforts should be made to address this disparity to help drive equality between these two services. <h3>Disclosure of Interest</h3> None Declared
Influence of Polymorphisms of Pro-Inflammatory (IL-12, TNFa and LTa) and Anti-Inflammatory Factors (IL-10 and CTLA4) in Autoimmune Hemolytic Anemia.
Authors: Maria S. Figueiredo, Leandro S. D’Abronzo, Melca M. Oliveira, Juliana L. Dreyfuss, Jose Orlando Bordin
Journal: Blood (2007)